Progressive Multifocal Leukoencephalopathy in Patients Treated with Chimeric Antigen Receptor T Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Nov 4

PMID 36332168

Authors

Adam Goldman

Emanuel Raschi

Joab Chapman

Bianca D Santomasso

Marcelo C Pasquini

Miguel-Angel Perales

Roni Shouval

Affiliations

Soon will be listed here.

Citing Articles

Progressive multifocal leukoencephalopathy after CAR-T cell therapy.

Montoya M, Harmsen H, Baer B, Long N, Messimore A, Jayani R Bone Marrow Transplant. 2024; 59(12):1780-1782.

PMID: 39256585 DOI: 10.1038/s41409-024-02410-3.

CAR-T Cells and the Kidney: Insights from the WHO Safety Database.

Gerard A, Merino D, Charbinat A, Fournier J, Destere A, Loschi M BioDrugs. 2023; 37(4):521-530.

PMID: 37166707 PMC: 10287817. DOI: 10.1007/s40259-023-00599-1.

References

Sdrimas K, Diaz-Paez M, Camargo J, Lekakis L . Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol. 2020; 112(1):118-121. DOI: 10.1007/s12185-020-02840-x. View

Carson K, Evens A, Richey E, Habermann T, Focosi D, Seymour J . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113(20):4834-40. PMC: 2686134. DOI: 10.1182/blood-2008-10-186999. View

Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L . CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513. PMC: 8893508. DOI: 10.1182/blood.2020010543. View

Mackenzie S, Shafat M, Roddy H, Hyare H, Neill L, Marzolini M . Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report. EJHaem. 2022; 2(4):848-853. PMC: 9281485. DOI: 10.1002/jha2.274. View

Bennett C, Focosi D, P Socal M, Bian J, Nabhan C, Hrushesky W . Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021; 8(8):e593-e604. DOI: 10.1016/S2352-3026(21)00167-8. View

Mian A, Andrapalliyal N, Weathers A, Pohlman B, Hill B . Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy. Eur J Haematol. 2021; 106(4):584-588. DOI: 10.1111/ejh.13583. View

Bartsch T, Rempe T, Leypoldt F, Riedel C, Jansen O, Berg D . The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol. 2019; 26(4):566-e41. DOI: 10.1111/ene.13906. View

Major E, Yousry T, Clifford D . Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018; 17(5):467-480. DOI: 10.1016/S1474-4422(18)30040-1. View

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

10.

Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah N . Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013; 93(6):539-46. PMC: 3857139. DOI: 10.1038/clpt.2013.24. View

11.

Cortese I, Muranski P, Enose-Akahata Y, Ha S, Smith B, Monaco M . Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019; 380(17):1597-1605. DOI: 10.1056/NEJMoa1815039. View

12.

Cortese I, Reich D, Nath A . Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2020; 17(1):37-51. PMC: 7678594. DOI: 10.1038/s41582-020-00427-y. View

13.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

14.

Alstadhaug K, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch H . Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 2014; 71(8):1030-5. DOI: 10.1001/jamaneurol.2014.825. View

15.

Strati P, Varma A, Adkins S, Nastoupil L, Westin J, Hagemeister F . Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2020; 106(10):2667-2672. PMC: 8485681. DOI: 10.3324/haematol.2020.254045. View

16.

Baird J, Epstein D, Tamaresis J, Ehlinger Z, Spiegel J, Craig J . Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021; 5(1):143-155. PMC: 7805341. DOI: 10.1182/bloodadvances.2020002732. View

17.

Mackenzie S, Laurence A, OReilly M, Peggs K, Roddie C . Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy. Lancet Haematol. 2021; 8(12):e870-e873. DOI: 10.1016/S2352-3026(21)00316-1. View

18.

Cortese I, Beck E, Al-Louzi O, Ohayon J, Andrada F, Osuorah I . BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021; 20(8):639-652. PMC: 8395368. DOI: 10.1016/S1474-4422(21)00174-5. View

19.

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

20.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366(20):1870-80. DOI: 10.1056/NEJMoa1107829. View